The proxy war in Ukraine is heading to a denouement with the US and Russia dividing the spoils while the European powers stand bewildered by events they have been wilfully blind to, says KEVIN OVENDEN
Public pharma v abusive prices: the case of the latest HIV-prevention drug
ALAN ROSSI SILVA argues that Gilead’s HIV prevention drug, while promising, highlights systemic failures in the pharmaceutical industry, showing the need to shift towards state-owned drug development and production
One can only imagine what would happen if 2.2 million Palestinian refugees were pushed into Jordan, Egypt and other Arab countries, per Trump’s proposal, writes RAMZY BAROUD
This is the most anti-migrant government in decades, argues RAVISHAAN RAHEL MUTHIAH
VICTOR GROSSMAN reports, with a little chuckle, on how US readiness to work with Russia, not just on peace for Ukraine, has thrown a spanner into the German electoral machine
SOLOMON HUGHES probes the finances of a phoney ‘charity’ pushing the free schools and academies agenda
Freedom now for former PM Mir-Hossein Mousavi and other political prisoners
VIJAY PRASHAD examines why in 2018 Washington started to take an increasingly belligerent stance towards ‘near peer rivals’ – Russa and China – with far-reaching geopolitical effects
LENACAPAVIR, an injectable antiretroviral drug developed by Gilead Sciences, recently made headlines after a Phase 3 clinical trial in South Africa and Uganda showed it to be 100 per cent effective in preventing HIV among women and adolescent girls.
Though hailed as a breakthrough in HIV prevention, lenacapavir serves as a stark reminder of the problems with the pricing of life-saving medicines.
While further data from this study and results from studies involving other populations are needed, lenacapavir could be considered the most durable HIV prevention method to show efficacy among women — a population for who biomedical HIV prevention evidence has been severely limited.
Similar stories
Despite miraculous trial results showing new treatment could halt transmission, corporate greed and patent laws condemn millions to preventable infection and death, write ROX MIDDLETON, LIAM SHAW and MIRIAM GAUNTLETT
